CONMED (CNMD) was upgraded by Wells Fargo & Company to "hold".
CONMED (CNMD) was downgraded by Piper Sandler from "overweight" to "neutral". They now have a $39.00 price target on the stock.
CONMED (NYSE:CNMD) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
CONMED (NYSE:CNMD) had its price target raised by analysts at Wells Fargo & Company from $41.00 to $42.00. They now have an "equal weight" rating on the stock.
CONMED (NYSE:CNMD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.